Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 110, Issue 1, Pages 78-86
Publisher
Oxford University Press (OUP)
Online
2017-05-09
DOI
10.1093/jnci/djx118
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
- (2016) David Lorente et al. Clinical Genitourinary Cancer
- Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies
- (2016) S. Volik et al. MOLECULAR CANCER RESEARCH
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
- (2016) Akash Kumar et al. NATURE MEDICINE
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
- (2016) Peter Ulz et al. Nature Communications
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2016) Alexander W. Wyatt et al. JAMA Oncology
- Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
- (2015) K. Chi et al. ANNALS OF ONCOLOGY
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
- (2015) Eleni Efstathiou et al. EUROPEAN UROLOGY
- The evolutionary history of lethal metastatic prostate cancer
- (2015) Gunes Gundem et al. NATURE
- Switching and withdrawing hormonal agents for castration-resistant prostate cancer
- (2015) David Lorente et al. Nature Reviews Urology
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell-free DNA Analysis for Noninvasive Examination of Trisomy
- (2015) Mary E. Norton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer
- (2015) Matthew K.H. Hong et al. Nature Communications
- The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
- (2015) Shusuke Akamatsu et al. Cell Reports
- Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer
- (2014) R R McKay et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Tumor clone dynamics in lethal prostate cancer
- (2014) S. Carreira et al. Science Translational Medicine
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation